Aardvark Therapeutics (NASDAQ:AARD) Raised to "Hold" at Wall Street Zen

Aardvark Therapeutics (NASDAQ:AARD - Get Free Report) was upgraded by investment analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a research report issued to clients and investors on Friday.

A number of other research firms also recently commented on AARD. Morgan Stanley assumed coverage on Aardvark Therapeutics in a research note on Monday, March 10th. They issued an "overweight" rating and a $29.00 price objective for the company. Royal Bank of Canada dropped their price objective on Aardvark Therapeutics from $21.00 to $20.00 and set an "outperform" rating for the company in a research note on Thursday, May 15th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $50.00 price objective on shares of Aardvark Therapeutics in a research note on Tuesday, April 1st. Finally, Bank of America lifted their price objective on Aardvark Therapeutics from $22.00 to $26.00 and gave the company a "buy" rating in a research note on Thursday, March 27th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $31.25.

Aardvark Therapeutics Price Performance

Shares of NASDAQ AARD traded down $0.14 during midday trading on Friday, hitting $11.81. The stock had a trading volume of 29,676 shares, compared to its average volume of 102,223. Aardvark Therapeutics has a 1 year low of $4.88 and a 1 year high of $19.58. The company's 50 day simple moving average is $9.52.

Aardvark Therapeutics (NASDAQ:AARD - Get Free Report) last posted its earnings results on Wednesday, May 14th. The company reported ($0.71) EPS for the quarter, missing analysts' consensus estimates of ($0.70) by ($0.01).

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Decheng Capital LLC purchased a new stake in Aardvark Therapeutics during the first quarter worth approximately $29,419,000. Cormorant Asset Management LP purchased a new stake in Aardvark Therapeutics during the first quarter worth approximately $6,009,000. Braidwell LP purchased a new stake in Aardvark Therapeutics during the first quarter worth approximately $3,755,000. Adage Capital Partners GP L.L.C. purchased a new stake in Aardvark Therapeutics during the first quarter worth approximately $1,878,000. Finally, Goldman Sachs Group Inc. purchased a new stake in Aardvark Therapeutics during the first quarter worth approximately $153,000.

Aardvark Therapeutics Company Profile

Aardvark Therapeutics, Inc operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.